Multiple Myeloma: International Myeloma Foundation : •health professionals   : webcasts : Amplification of 1q21 Is Associated with Poor Outcome after Treatment with Bortezomib in Relapsed/Refractory Multiple Myeloma

We are international

webcasts

back

Amplification of 1q21 Is Associated with Poor Outcome after Treatment with Bortezomib in Relapsed/Refractory Multiple Myeloma

By Heinz Ludwig, MD

	12.17.06
Amplification of 1q21 Is Associated with Poor Outcome after Treatment with Bortezomib in Relapsed/Refractory Multiple Myeloma Be the first to comment	print share \| related articles